Focused on novel, nanotechnology-based therapeutics
Oliver Fetzer, Ph.D.
President and Chief Executive Officer
Before joining Cerulean, Oliver was Senior Vice President, Corporate Development and Research and Development at Cubist Pharmaceuticals (NASDAQ: CBST). While at Cubist, his responsibilities included Corporate Development, Business Development, Drug Discovery Research, Non-Clinical Development, Clinical Development, Chemical Development, Medical Affairs, and Program Management. Prior to joining Cubist, Oliver served as a Managing Director and Partner at the Boston Consulting Group (BCG) in the firm’s healthcare practice where he was responsible for projects in strategy, operational effectiveness, and mergers and integration. He worked with clients both in and outside of healthcare while he was stationed at the BCG offices located in Boston, Auckland, and Munich. While at BCG, Oliver also led the Associate recruiting effort for the Boston office and was a member of the Career Development Committee. Early in his career, Oliver worked at Bayer AG where he was involved in chemistry and pharmaceutics.
Oliver is presently a director of Auxilium Pharmaceuticals (NASDAQ: AUXL) and Cerulean Pharma. He received his B.S. in Biochemistry from the College of Charleston, Ph.D. in Pharmaceutical Sciences from the Medical University of South Carolina, and an MBA from Carnegie Mellon University.
David P. DeMagistris, Ph.D.
Senior Vice President, Pharmaceutical Sciences and Manufacturing
Scott Eliasof, Ph.D.
Senior Director, Research
Alexandra Glucksmann, Ph.D.
Senior Vice President, Research and Business Operations
Senior Vice President, Finance and Administration
John Ryan, Ph.D., M.D.
Senior Vice President and Chief Medical Officer
Jean Silveri, J.D.
Senior Vice President, General Counsel
Senior Director, Pharmaceutical Sciences and Manufacturing
Cissy Young, Ph.D.
Director, Strategy and Business Development